Sarcopenia
Conditions
Interventions
This is a randomized, controlled, double-blind, crossover clinical study. Experimental group: 58 individuals diagnosed with Alzheimers disease will receive 10 grams of a supplement composed of 5 grams
D12.125.373
Sponsors
Universidade Federal de Minas Gerais - UFMG
Instituto Nacional de Neurociência Translacional (INNT)
Eligibility
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 58 individuals (men and women); age equal to or over; Medical diagnosis of mild cognitive impairment or mild to moderate dementia due to or diagnosed with mixed dementia (from associated with cerebrovascular disease); Preserved ability to walk at least 10 meters without aid of gear devices and able to participate in the proposed interventions and evaluations.
Exclusion criteria
Exclusion criteria: Motor stroke motor sequelae; Other neurological diseases that affect cognition and/or mobility; functional limitation or sensory impairment; Parkinsonism; Some decompensated and/or renal cardiovascular condition - glomerular filtration rate (TFG) less than 40 ml/min/1.73 m2; presence of high microalbuminuria or proteinuria; diagnosed with type 1 diabetes mellitus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess changes in functionality, determined through dynamometry, bioimpedance and Timed Up and Go (TUG) at the beginning of the study and at the end of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess changes in body composition, determined through anthropometric measurements and bioimpedance at baseline and end of study.;To assess change in cognitive function, as determined using the Revised Addenbrooke's Cognitive Examination (ACE-R), at baseline and end of study.;To assess changes in levels of metabolic and inflammation markers, determined through laboratory tests, at baseline and at the end of the study. | — |
Countries
Brazil
Contacts
Public ContactPaulo Caramelli
Universidade Federal de Minas Gerais - UFMG
Outcome results
None listed